These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11944274)

  • 21. [Investigation of chemotherapy based on enzyme expression and drug sensitivity test in colorectal cancer].
    Tokunaga Y; Ohnishi T; Sasaki H
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):69-73. PubMed ID: 21368461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    Oestreicher P
    ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
    [No Abstract]   [Full Text] [Related]  

  • 23. Oxaliplatin in colorectal cancer: current studies.
    Goldberg R
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 11):42-7. PubMed ID: 11204663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From the Food and Drug Administration.
    Crawford LM
    JAMA; 2002 Sep; 288(10):1225. PubMed ID: 12215114
    [No Abstract]   [Full Text] [Related]  

  • 25. Eloxatin (Oxaliplatin) for Cancer Therapy 2002. Abstracts.
    Onkologie; 2002 Aug; 25 Suppl 3():1-42. PubMed ID: 12389591
    [No Abstract]   [Full Text] [Related]  

  • 26. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gleaning from the American Oncology Congress. A new standard in colorectal carcinoma].
    MMW Fortschr Med; 2002 Oct; 144(41):61. PubMed ID: 12474374
    [No Abstract]   [Full Text] [Related]  

  • 28. New treatments for colon cancer.
    Slevin M; Payne S
    BMJ; 2004 Jul; 329(7458):124-6. PubMed ID: 15258046
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapy in metastatic colorectal cancer.
    Christopoulou A
    Tech Coloproctol; 2004 Nov; 8 Suppl 1():s43-6. PubMed ID: 15655639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin in the treatment of colorectal cancer.
    Kim GP; Erlichman C
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanism of action and pharmacology of new organometallic compounds active in the treatment of colorectal neoplasms].
    Marchetti P; Gallà DA; Cifone G; Ricevuto E; Ficorella C
    Tumori; 2000; 86(3 Suppl):S6-8. PubMed ID: 10969607
    [No Abstract]   [Full Text] [Related]  

  • 32. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
    Rosa DD; Ismael GF; de Azambuja E; Braga S; Cardoso F; Bleiberg H
    J Clin Oncol; 2006 Nov; 24(32):5176-7; author reply 5177. PubMed ID: 17093286
    [No Abstract]   [Full Text] [Related]  

  • 34. [Oxaliplatin (Eloxatin). Progress in cancer therapy].
    Onkologie; 2001 Aug; 24 Suppl 4():1-41. PubMed ID: 11592268
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version.
    Zalinski S; Mariette C; Farges O; ; ;
    J Visc Surg; 2011 Jun; 148(3):e171-82. PubMed ID: 21703959
    [No Abstract]   [Full Text] [Related]  

  • 36. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
    Schrag D; Weiser M; Schattner M; Shia J; Akhurst T
    J Clin Oncol; 2005 Mar; 23(9):1799-802. PubMed ID: 15774773
    [No Abstract]   [Full Text] [Related]  

  • 37. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    Nipp RD; Ryan DP
    Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance tests were not mentioned.
    Lippert TH
    Dtsch Arztebl Int; 2010 Jun; 107(22):399; author reply 399-400. PubMed ID: 20574557
    [No Abstract]   [Full Text] [Related]  

  • 39. The challenge to optimize medical therapy for advanced colorectal cancer.
    Hubbard JM; Grothey A
    J Natl Cancer Inst; 2014 Feb; 106(2):djt442. PubMed ID: 24511110
    [No Abstract]   [Full Text] [Related]  

  • 40. Platinum antitumour agents.
    Dabrowiak JC; Bradner WT
    Prog Med Chem; 1987; 24():129-58. PubMed ID: 3332917
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.